The FDA is overcautious on consumer genomics

Science & Society’s Nita Farahany and Harvard’s Robert Green argue that the FDA’s recent clampdown on 23&Me’s Saliva Collection Kit and personal genome services is unwarranted without evidence of harm. Regulatory constraints might stifle emerging products in consumer genomics that could make society healthier and empower patient-driven healthcare. Read More